Trade Names:Cefizox- Powder for Injection 500 mg (2.6 mEq sodium/g)- Powder for Injection 1 g (2.6 mEq sodium/g)- Powder for Injection 2 g (2.6 mEq sodium/g)- Powder for Injection 10 g (2.6 mEq sodium/g)- Injection 1 g as sodium- Injection 2 g as sodium
Inhibits mucopeptide synthesis in bacterial cell wall.
Ceftizoxime is 30% protein bound. It achieves therapeutic levels in various body fluids (eg, CSF in those with inflamed meninges) and body tissues. It is excreted in human milk in low concentrations.
Ceftizoxime is not metabolized.
The t ½ is about 1.7 h. Ceftizoxime is excreted unchanged by the kidneys in 24 h.
The t ½ is prolonged. Dosage adjustment is recommended.
Treatment of infections of lower respiratory tract, urinary tract, skin and skin structures, bone and joint; treatment of intra-abdominal infections, pelvic inflammatory disease, gonorrhea, septicemia, and meningitis caused by susceptible microorganisms.
Hypersensitivity to cephalosporins.
IV/IM 1 to 2 g every 8 to 12 h (life-threatening infections: IV up to 2 g every 4 h or 3 to 4 g every 8 h).Children older than 6 mo of age
IV/IM 50 mg/kg every 6 to 8 h up to 200 mg/kg/day (max, 12 g/day).
Increased risk of nephrotoxicity.Probenecid
Inhibition of renal excretion of ceftizoxime.
Do not add aminoglycosides to ceftizoxime solutions because inactivation of both drugs may result; administer at separate sites if concurrent therapy is indicated.
May cause false-positive urine glucose test results with Benedict solution, Fehling solution, or Clinitest tablets but not with enzyme-based tests (eg, Clinistix , Tes-tape ); false-positive test results for proteinuria with acid and denaturization-precipitation tests; false-positive direct Coombs test results in certain patients (eg, those with azotemia); false elevations in urinary 17-ketosteroid values.
Nausea; vomiting; diarrhea; anorexia; abdominal pain or cramps; flatulence; colitis, including pseudomembranous colitis.
Pyuria; renal function impairment; dysuria; reversible interstitial nephritis; hematuria; toxic nephropathy.
Eosinophilia; neutropenia; lymphocytosis; leukocytosis; thrombocytopenia; decreased platelet function; anemia; aplastic anemia; hemorrhage.
Hepatic function impairment; abnormal LFT results.
Hypersensitivity, including Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis; candidal overgrowth; serum sickness–like reactions (eg, skin rashes, polyarthritis, arthralgia, fever); phlebitis; thrombophlebitis and pain at injection site.
MonitorResponse to therapy
Monitor patient's response to therapy. Notify health care provider if infection does not appear to improve or worsens.Adverse reactions
Monitor patient for GI, DERM, and general body adverse reactions, and signs of superinfection. Inform health care provider if noted and significant. Immediately report severe diarrhea, diarrhea containing blood or pus, or severe abdominal cramping.
Category B .
Excreted in breast milk.
Safety and efficacy in infants younger than 6 mo of age not established. In infants, consider benefits relative to risks.
Reactions range from mild to life-threatening. Administer drug with caution to penicillin-sensitive patients because of possible cross-reactivity.
Use drug with caution in patients with baseline renal function impairment. Dosage adjustment based on renal function may be required.
May result in bacterial or fungal overgrowth of nonsusceptible micro-organisms.
Consider in patients who develop diarrhea.
Copyright © 2009 Wolters Kluwer Health.